Ying Cheng
About
Ying Cheng is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology.
According to data from OpenAlex, Ying Cheng has authored 48 papers receiving a total of 269 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 26 papers in Pulmonary and Respiratory Medicine and 9 papers in Molecular Biology. Recurrent topics in Ying Cheng's work include Lung Cancer Treatments and Mutations (18 papers), Lung Cancer Research Studies (13 papers) and Cancer Immunotherapy and Biomarkers (9 papers). Ying Cheng is often cited by papers focused on Lung Cancer Treatments and Mutations (18 papers), Lung Cancer Research Studies (13 papers) and Cancer Immunotherapy and Biomarkers (9 papers). Ying Cheng collaborates with scholars based in China, United States and Japan. Ying Cheng's co-authors include Xingya Li, Peng Zhang, Mafei Kang, Yan Yu, Dingzhi Huang, Yu Zhang, Zhen Wang, Wenjuan Zheng, Shiangjiin Leaw and Yanqiu Zhao and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Journal of Thoracic Oncology.
In The Last Decade
Ying Cheng
42 papers receiving 268 citations
Hit Papers
Peers
Ying Cheng
Xiangjuan Ma China
M. Dómine Gómez Spain
Weiheng Hu China
Moises J. Velez United States
Guangming Tian China
Ahmed Bilal Khalid United States
Linpeng Zheng China
Ling Dai China
J.-S. Lee South Korea
Yuki Takeyasu Japan
Citations per year, relative to Ying Cheng Ying Cheng (= 1×)
peers
Xiangjuan Ma
Countries citing papers authored by Ying Cheng
Since
Specialization
Citations
This map shows the geographic impact of Ying Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ying Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ying Cheng more than expected).
Fields of papers citing papers by Ying Cheng
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Ying Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ying Cheng. The network helps show where Ying Cheng may publish in the future.
Co-authorship network of co-authors of Ying Cheng
This figure shows the co-authorship network connecting the top 25 collaborators of Ying Cheng. A scholar is included among the top collaborators of Ying Cheng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ying Cheng. Ying Cheng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Cheng, Ying, Mingjie Zhou, Shuguang Wang, et al.. (2025). Exploring anxiolytic peptides derived from walnut protein by an integrated approach of multivariate analysis, random forest methodology. Food Bioscience. 66. 106271–106271.
2.
Cheng, Ying, Panpan Zhang, Ming Lu, et al.. (2025). Efficacy and safety of surufatinib plus toripalimab in treatment-naive, PD-L1-positive, advanced or metastatic non-small-cell lung cancer and previously treated small-cell lung cancer: an open-label, single-arm, multicenter, multi-cohort phase II trial. Cancer Immunology Immunotherapy. 74(3). 83–83.
3.
Cheng, Ying, Quan Lin, Yanyan Jiang, et al.. (2025). Quercetin can improve anesthesia induced neuroinflammation and cognitive dysfunction by regulating miR-138-5p/ LCN2. BMC Anesthesiology. 25(1). 21–21.
4.
Duo, Fang, Hainan Zhao, Lu Pei, et al.. (2025). Diprovocim protects against the radiation-induced damage via the TLR2 signaling pathway. Molecular Medicine. 31(1). 139–139.
5.
Du, Bin, Kang Chen, Jie Meng, et al.. (2024). Iron promotes both ferroptosis and necroptosis in the early stage of reperfusion in ischemic stroke. Genes & Diseases. 11(6). 101262–101262.
6.
Duo, Fang, et al.. (2024). Scleroglucan protects the intestine from irradiation-induced injury by targeting the IL-17 signaling pathway. International Immunopharmacology. 129. 111614–111614.
7.
Cheng, Ying, Lin Wu, Yong Fang, et al.. (2024). Abstract CT248: Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2 mutant non-small cell lung cancer (NSCLC): primary analysis from the Phase 2 DESTINY-Lung05 (DL-05) trial. Cancer Research. 84(7_Supplement). CT248–CT248.
8.
Wang, Feng, Junjie Peng, Xinjun Liang, et al.. (2024). First-line serplulimab plus HLX04 and XELOX versus placebo plus bevacizumab and XELOX in metastatic colorectal cancer: A phase 2/3 study.. Journal of Clinical Oncology. 42(16_suppl). 3569–3569.
9.
Ma, Xianjun, et al.. (2024). Trends and Prospects of Low-Density Lipoprotein Cholesterol in Stroke: A Bibliometric Analysis. Cureus. 16(9). e69492–e69492.
10.
Cheng, Ying, Liang Han, Lin Wu, et al.. (2024). Serplulimab vs. placebo combined with chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: Extended follow-up results and patient-reported outcomes from the international phase 3 ASTRUM-005 study.. Journal of Clinical Oncology. 42(16_suppl). 8100–8100.
11.
Ma, Fei, Fuming Qiu, Zhongsheng Tong, et al.. (2024). Updated efficacy of anti-TROP2 ADC ESG401 for first-line metastatic TNBC in phase 1b study.. Journal of Clinical Oncology. 42(23_suppl). 2–2.
12.
Li, Shuang, et al.. (2024). The efficacy and safety of immunotherapy as first−line treatment for extensive-stage small cell lung cancer: evaluating based on reconstructed individual patient data. Frontiers in Oncology. 14. 1371313–1371313.
13.
Zhang, Panpan, Zhendong Chen, Si Shi, et al.. (2024). Efficacy and safety of surufatinib plus toripalimab, a chemotherapy-free regimen, in patients with advanced gastric/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, or biliary tract cancer. Cancer Immunology Immunotherapy. 73(7). 119–119.
14.
Xu, Rui‐Hua, Feng Wang, Junjie Peng, et al.. (2024). First-line serplulimab plus HLX04 and XELOX versus placebo plus bevacizumab and XELOX in metastatic colorectal cancer: A phase 2/3 study.. Journal of Clinical Oncology. 42(3_suppl). 124–124.
15.
Lv, Dongqing, Jiuwei Cui, Zhen Wang, et al.. (2024). A phase Ib/IIa trial to evaluate the safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced NSCLC.. Journal of Clinical Oncology. 42(16_suppl). 8533–8533.
16.
Shi, Yuankai, Lin Gui, Ying Cheng, et al.. (2024). A phase II multicenter study of abexinostat, an oral histone deacetylase inhibitor, in patients with relapsed/refractory follicular lymphoma.. Journal of Clinical Oncology. 42(16_suppl). 7059–7059.
17.
Wang, Jie, Zhijie Wang, Lin Wu, et al.. (2023). Final overall survival and biomarker analyses of CHOICE-01: A double-blind randomized phase 3 study of toripalimab versus placebo in combination chemotherapy for advanced NSCLC without EGFR/ALK mutations.. Journal of Clinical Oncology. 41(16_suppl). 9003–9003.
18.
Wang, Jiayu, Qingyuan Zhang, Tao Sun, et al.. (2023). A multicenter, single-arm, open-label trial of birociclib, a CDK4/6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer.. Journal of Clinical Oncology. 41(16_suppl). 1072–1072.
19.
Wang, Jie, Zhijie Wang, Lin Wu, et al.. (2022). Final progression-free survival, interim overall survival, and biomarker analyses of CHOICE-01: A phase III study of toripalimab versus placebo in combination with first-line chemotherapy for advanced NSCLC without EGFR/ALK mutations. Journal of Clinical Oncology. 40(36_suppl). 362936–362936.
20.
Cheng, Ying, Liang Han, Lin Wu, et al.. (2022). Serplulimab, a novel anti-PD-1 antibody, plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small-cell lung cancer: An international randomized phase 3 study.. Journal of Clinical Oncology. 40(16_suppl). 8505–8505.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Xiangjuan Ma Breakdown of academic impact, for papers by M. Dómine Gómez Breakdown of academic impact, for papers by Weiheng Hu Breakdown of academic impact, for papers by Moises J. Velez Breakdown of academic impact, for papers by Guangming Tian Breakdown of academic impact, for papers by Ahmed Bilal Khalid Breakdown of academic impact, for papers by Linpeng Zheng Breakdown of academic impact, for papers by Ling Dai Breakdown of academic impact, for papers by J.-S. Lee Breakdown of academic impact, for papers by Yuki Takeyasu